KU ASH 2018 Review: Current Updates in Hematologic Diseases
Avatar

ASH 2018 AML: Deciding Between Standard vs Investigational Therapies & Problems in Evaluating New Therapies, MRD and HCT

By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Elihu H. Estey
By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Elihu H. Estey
571 views
March 19, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Playlist AML - Keynote - Latest updates on Standard Therapies and Investigational Therapies, MRD in AML, HTC and Non-HCT

23:37
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML: Deciding Between Standard vs Investigational Therapies…

Feat. E. Estey
05:54
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Re…

Feat. E. Estey
06:26
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantat…

Feat. E. Estey
14:49
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML Challenges in Evaluating New Therapies: Understanding t…

Feat. E. Estey
Thumbs Up
  • 459 views
  • March 19, 2019

Recommended

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views
22:37

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views
19:01

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

602 views
27:49

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

707 views
17:51

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

884 views
19:21

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

495 views
31:53

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

734 views
21:51

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

564 views
27:26

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

458 views
28:02

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

734 views
22:30

Emerging Treatment Options for AML in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Perl

695 views
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

884 views
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

466 views
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

419 views
02:01

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

341 views
34:57

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

459 views
04:16

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

396 views
48:04

Integrating Targeted Therapies in AML

Icahn School of Medicine at Mount Sinai

H. Kantarjian

411 views
11:35

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

253 views
AUTOPLAY